- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01013831
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung
A Phase I Study of Erlotinib in Patients With Premalignant Lesions of the Lung
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To determine the lowest dose of erlotinib (erlotinib hydrochloride) that will decrease the ratio of phosphorylated to total epidermal growth factor receptor (EGFR) (phosphorylated EGFR [pEGFR]/EGFR) by at least 20% in subjects with premalignant lesions of the lung. This will be accomplished by implementing a dose de-escalation trial of erlotinib (i.e., 75, 50, and 25 or 100 mg by mouth daily for a 3-month period), and determining the pEGFR/EGFR ratio in premalignant lesions of the lung epithelium by immunohistochemistry. Changes in the pEGFR/EGFR ratio will be assessed by comparing the pre-treatment (baseline) ratio to that of the post-treatment (3 month) ratio, measured in paraffin embedded biopsy specimens.
SECONDARY OBJECTIVES:
I. To determine the effect of erlotinib on the following biomarkers of potential biological relevance in paraffin embedded lung biopsies, p-v-akt murine thymoma viral oncogene homolog 1 (Akt), p-mitogen-activated protein kinase 1 (Erk), and marker of proliferation Ki-67 (Ki67).
II. To characterize the toxicity profile of erlotinib in this cohort of subjects.
III. To analyze and model erlotinib's pharmacokinetic/pharmacodynamic (PK/PD) profile. Serial blood samples will be drawn at the beginning and at the end of erlotinib treatment, and pharmacokinetic parameters will be determined. The status of EGFR genotype (and that of others genes linked to erlotinib PK/PD) clinical toxicity, and dose will be examined as possible other influential covariates by comparing them to experimentally measured PK profiles, and PD profiles (in particular, the pEGFR/EGFR ratio). The goal of these studies will be to determine the optimal biologic concentration (OBC) of Erlotinib that is associated with the lowest toxicity and highest effect, for a given subject's pharmacogenomic profile.
OUTLINE:
Patients receive erlotinib hydrochloride orally (PO) once daily (QD) for 90 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02118
- Boston University School Of Medicine
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Roswell Park Cancer Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of a premalignant lung lesion (metaplasia or dysplasia) on autofluorescent bronchoscopy (AFB) within 1 month
- Participants must have a >= 10 pack year lifetime smoking history; current and former smokers only are eligible for this trial
- No contraindications for treatment with erlotinib or additional bronchoscopies
- Absolute neutrophil count (ANC) of >= 1.5 x 10^9/L
- Platelet count of >= 100 x 10^9/L
- Creatinine level of less than 1.5 mg/dL
- Total bilirubin =< 2.0 mg/dl
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
- Alkaline phosphatase =< 2.5 x ULN
- Must meet Eastern Cooperative Oncology Group (ECOG) performance status criteria of 0-1
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) throughout the duration of the study and for 1 month following cessation of study drug; females must begin adequate contraception immediately following screening pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; if she is pregnant, she will be immediately withdrawn from the study
- Ability to understand and the willingness to sign a written institutional review board (IRB) approved informed consent document
Exclusion Criteria:
- Subjects with life-threatening medical conditions that would preclude the treatment intervention and bronchoscopy, including, but not limited to, unstable pulmonary function, acute cardiac failure, which is unstable despite medication use; uncontrolled hypertension; uncontrolled diabetes mellitus; unstable coronary artery disease; acute or chronic liver disease, ongoing or active infection; or psychiatric illness/social situations that would limit compliance with study requirements
- Participants with evidence of an active cancer or carcinoma in situ, are not eligible
- Participants currently taking medications that induce or inhibit the cytochrome P450, family 3, subfamily A, polypeptide 4-7 (CYP3A4-7) enzymes
- Participants may not be receiving any other investigational agents within 3 months
- Participants taking warfarin
- History of allergic reactions attributed to erlotinib, a known hypersensitivity to erlotinib, or agents with a similar chemical or biological composition to erlotinib
- Women who are pregnant or lactating are excluded from the study because based on the proposed mechanism of tyrosine kinase inhibition of erlotinib; erlotinib should be assumed to cause fetal harm when administered to a pregnant woman; there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with erlotinib
- History of interstitial lung disease (ILD)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Prevention (erlotinib hydrochloride)
Patients receive erlotinib hydrochloride PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
|
Gitt PO
Andre navn:
Korrelative studier
Korrelative studier
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in the ratio of p-EGFR to total EGFR
Tidsramme: Baseline up to 90 days
|
Baseline up to 90 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in the expression of p-Akt
Tidsramme: Baseline up to 90 days
|
Analyzed using an analysis-of-variance (ANOVA) on the change from baseline expression level with a factor for dose (75, 50, 25 or 100).
All tests will be two-sided and tested at level alpha=0.05.
If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments.
|
Baseline up to 90 days
|
Change in the expression of p-Erk
Tidsramme: Baseline up to 90 days
|
Analyzed using an ANOVA on the change from baseline expression level with a factor for dose (75, 50, 25 or 100).
All tests will be two-sided and tested at level alpha=0.05.
If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments.
|
Baseline up to 90 days
|
Change in the expression of Ki67
Tidsramme: Baseline up to 90 days
|
Analyzed using an ANOVA on the change from baseline expression level with a factor for dose (75, 50, 25 or 100).
All tests will be two-sided and tested at level alpha=0.05.
If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments.
|
Baseline up to 90 days
|
Incidence of toxicities, graded according to Common Toxicity Criteria, version 3.0
Tidsramme: Up to 30 days
|
Up to 30 days
|
Andre resultatmål
Resultatmål |
Tidsramme |
---|---|
PK/PD parameters
Tidsramme: Up to 90 days
|
Up to 90 days
|
Pharmacogenomic profile
Tidsramme: Up to 90 days
|
Up to 90 days
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NCI-2013-00750 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- P30CA060553 (U.S. NIH-stipend/kontrakt)
- N01CN35157 (U.S. NIH-stipend/kontrakt)
- RPCI-I-121507
- NU-NWU08-11-01
- STU00012618
- NCI 08-11-01 (Annen identifikator: Northwestern University)
- NWU08-11-01 (Annen identifikator: DCP)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Metaplasi
-
Shandong UniversityFullført
-
University of Medicine and Dentistry of New JerseyNational Institutes of Health (NIH)AvsluttetEsophageal metaplasiForente stater
-
National University Hospital, SingaporeNational Medical Research Council (NMRC), SingaporeUkjentIntestinal metaplasi | Intestinal dysplasiSingapore
-
The University of Hong KongFullførtIntestinal metaplasi | Gastrisk dysplasiHong Kong
-
King Chulalongkorn Memorial HospitalRekruttering
-
Washington University School of MedicineAvsluttet
-
Shandong UniversityUkjentSammenheng mellom konfokale laserendomomikroskopiske (CLE) egenskaper og gastrisk slimhinnemikrobiomIntestinal metaplasi | Slimhinnemikrobiom | H.Pylori | Gastrisk neoplasiKina
-
CelgeneFullførtMyelofibrose | Myeloid metaplasi | Myelofibrose med myeloide metaplasiForente stater, Italia, Storbritannia, Østerrike, Spania
-
Shandong UniversityUkjentProbebasert konfokal laserendomomikroskopi | den operative koblingen på gastrisk intestinal metaplasi
-
Shandong UniversityRekrutteringKunstig intelligens | Intestinal metaplasi | Konfokal laserendomomikroskopiKina
Kliniske studier på Erlotinib hydroklorid
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern... og andre samarbeidspartnereFullført
-
PfizerFullførtKarsinom, ikke-småcellet lungeForente stater
-
M.D. Anderson Cancer CenterFullførtAvansert kreftForente stater
-
Merck Sharp & Dohme LLCFullført
-
National Cancer Institute (NCI)FullførtCervical plateepitelkarsinom | Tilbakevendende livmorhalskreftForente stater
-
Grupo de Investigación Clínica en Oncología RadioterapiaFullførtPlateepitelkarsinom i hode og nakkeSpania
-
University of ChicagoNational Cancer Institute (NCI)FullførtOndartet peritoneal mesotheliomaForente stater
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Genentech, Inc.FullførtKarsinom, ikke-småcellet lungeForente stater
-
National Cancer Institute (NCI)FullførtTilbakevendende prostatakreft | Uspesifisert voksen solid svulst, protokollspesifikk | Tilbakevendende blærekreft | Stadium IV blærekreft | Tilbakevendende kreft i bukspyttkjertelen | Stadium III Bukspyttkjertelkreft | Stadium IV Bukspyttkjertelkreft | Mannlig brystkreft | Stage IV brystkreft | Stadium IV... og andre forholdForente stater
-
PharmaMarFullførtAvanserte ondartede solide svulsterSpania, Forente stater